Cargando…
Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study
BACKGROUND: Low molecular heparin(LMWH) and sodium sulfadiazine heparin(FPX) are commonly used to prevent deep vein thrombosis(DVT) after total hip arthroplasty(THA). In this study, we compared the role of these drugs in preventing DVT after THA. METHODS: Patients who underwent unilateral THA at the...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684995/ https://www.ncbi.nlm.nih.gov/pubmed/38033454 http://dx.doi.org/10.2147/ORR.S431372 |
_version_ | 1785151532394610688 |
---|---|
author | Haibier, Abuduwupuer Yusufu, Alimujiang Lin, Hang Kayierhan, Aiben Abudukelimu, Yimuran Abudurexiti, Tuerhongjiang |
author_facet | Haibier, Abuduwupuer Yusufu, Alimujiang Lin, Hang Kayierhan, Aiben Abudukelimu, Yimuran Abudurexiti, Tuerhongjiang |
author_sort | Haibier, Abuduwupuer |
collection | PubMed |
description | BACKGROUND: Low molecular heparin(LMWH) and sodium sulfadiazine heparin(FPX) are commonly used to prevent deep vein thrombosis(DVT) after total hip arthroplasty(THA). In this study, we compared the role of these drugs in preventing DVT after THA. METHODS: Patients who underwent unilateral THA at the Sixth Affiliated Hospital of Xinjiang Medical University from April 2020 to December 2022 were retrospectively analyzed for inclusion in this study. According to the anticoagulant drugs used, the patients were divided into LMWH group (n=106) and FPX group (n=97). Changes in perioperative coagulation-related indices, hemoglobin, blood loss And the postoperative complications. RESULTS: The preoperative indexes of the two groups of patients, the difference was not statistically significant (P>0.05); the indexes of Intraoperative blood loss, Visible blood loss, Hidden blood loss, and Total blood loss of the two groups of patients were compared, and the difference was not significant (P>0.05); PT activity and INR in the LMWH group were significantly lower than those in the FPX group on the 1st and 5th postoperative days, and the differences were significant (P<0.05); Platelets, Hemoglobin, Hematocrit, D-dimer, and Fibrinogen were compared between the two groups on the 1st and 5th postoperative days, and the differences were not significant (P<0.05). The differences were not significant (P>0.05). The differences in blood transfusion rate and blood volume between the two groups were not significant (P>0.05); the total hospitalization cost of the LMWH group was significantly lower than that of the FPX group, and the difference was significant (P<0.05); and the differences in the incidence of postoperative complications between the two groups were not significant (P>0.05). CONCLUSION: In this study, we found that the efficacy and safety of FPX and LMWH in preventing VTE after THA were basically the same, and the total cost of hospitalization in the LMWH group was significantly lower than that in the FPX group; however, due to the limited inclusion of the sample size, high-quality, large-sample, long-term follow-up clinical studies are necessary. |
format | Online Article Text |
id | pubmed-10684995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-106849952023-11-30 Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study Haibier, Abuduwupuer Yusufu, Alimujiang Lin, Hang Kayierhan, Aiben Abudukelimu, Yimuran Abudurexiti, Tuerhongjiang Orthop Res Rev Original Research BACKGROUND: Low molecular heparin(LMWH) and sodium sulfadiazine heparin(FPX) are commonly used to prevent deep vein thrombosis(DVT) after total hip arthroplasty(THA). In this study, we compared the role of these drugs in preventing DVT after THA. METHODS: Patients who underwent unilateral THA at the Sixth Affiliated Hospital of Xinjiang Medical University from April 2020 to December 2022 were retrospectively analyzed for inclusion in this study. According to the anticoagulant drugs used, the patients were divided into LMWH group (n=106) and FPX group (n=97). Changes in perioperative coagulation-related indices, hemoglobin, blood loss And the postoperative complications. RESULTS: The preoperative indexes of the two groups of patients, the difference was not statistically significant (P>0.05); the indexes of Intraoperative blood loss, Visible blood loss, Hidden blood loss, and Total blood loss of the two groups of patients were compared, and the difference was not significant (P>0.05); PT activity and INR in the LMWH group were significantly lower than those in the FPX group on the 1st and 5th postoperative days, and the differences were significant (P<0.05); Platelets, Hemoglobin, Hematocrit, D-dimer, and Fibrinogen were compared between the two groups on the 1st and 5th postoperative days, and the differences were not significant (P<0.05). The differences were not significant (P>0.05). The differences in blood transfusion rate and blood volume between the two groups were not significant (P>0.05); the total hospitalization cost of the LMWH group was significantly lower than that of the FPX group, and the difference was significant (P<0.05); and the differences in the incidence of postoperative complications between the two groups were not significant (P>0.05). CONCLUSION: In this study, we found that the efficacy and safety of FPX and LMWH in preventing VTE after THA were basically the same, and the total cost of hospitalization in the LMWH group was significantly lower than that in the FPX group; however, due to the limited inclusion of the sample size, high-quality, large-sample, long-term follow-up clinical studies are necessary. Dove 2023-11-24 /pmc/articles/PMC10684995/ /pubmed/38033454 http://dx.doi.org/10.2147/ORR.S431372 Text en © 2023 Haibier et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Haibier, Abuduwupuer Yusufu, Alimujiang Lin, Hang Kayierhan, Aiben Abudukelimu, Yimuran Abudurexiti, Tuerhongjiang Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study |
title | Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study |
title_full | Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study |
title_fullStr | Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study |
title_full_unstemmed | Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study |
title_short | Efficacy and Safety Study of Low-Molecular-Weight Heparin and Fondaparinux Sodium After Hip Arthroplasty: A Retrospective Cohort Study |
title_sort | efficacy and safety study of low-molecular-weight heparin and fondaparinux sodium after hip arthroplasty: a retrospective cohort study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684995/ https://www.ncbi.nlm.nih.gov/pubmed/38033454 http://dx.doi.org/10.2147/ORR.S431372 |
work_keys_str_mv | AT haibierabuduwupuer efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy AT yusufualimujiang efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy AT linhang efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy AT kayierhanaiben efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy AT abudukelimuyimuran efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy AT abudurexitituerhongjiang efficacyandsafetystudyoflowmolecularweightheparinandfondaparinuxsodiumafterhiparthroplastyaretrospectivecohortstudy |